Loading...
•
Mar 31, 2022
Dyne Therapeutics Q1 2022 Earnings Report
Reported financial results for the first quarter of 2022 and business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $35.6 million for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $323.2 million as of March 31, 2022.
Initiation of patient dosing in multiple ascending dose clinical trials for DYNE-251 in DMD and DYNE-101 in DM1 anticipated in mid-2022.
Response to FDA relating to IND for DYNE-251 in DMD is expected to be submitted in the second quarter.
Regulatory filings in multiple countries for DYNE-101 in DM1 are expected to be submitted in the second quarter.
Cash, cash equivalents and marketable securities were $323.2 million as of March 31, 2022, which is anticipated to fund operations into the second half of 2024.
Forward Guidance
Dyne expects to submit an IND for DYNE-301 in FSHD in the second half of 2022 and anticipates initiating patient dosing in global multiple ascending dose (MAD) clinical trials for DYNE-251 in DMD and DYNE-101 in DM1 in mid-2022.
Positive Outlook
- Submitting response to the FDA’s clinical hold letter for DYNE-251 in DMD in Q2 2022
- Submitting regulatory filings in multiple countries for DYNE-101 in DM1 in Q2 2022
- Initiating patient dosing in global multiple ascending dose (MAD) clinical trials for DYNE-251 in DMD in mid-2022
- Initiating patient dosing in global multiple ascending dose (MAD) clinical trials for DYNE-101 in DM1 in mid-2022
- Submitting an IND for DYNE-301 in FSHD in the second half of 2022
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...